Category: Stock Market

I’m always on the lookout for Australian stocks that could be market-beaters over the long-term. The market volatility over the last several months has definitely opened up an opportunity for investors to grab a great deal.

We don’t have to rush when it comes to investing, we can wait for the right opportunity to come along. Prices and economic conditions are always changing, so at some point we will get the opportunity we’re looking for.

I believe both businesses are undervalued for what they could achieve over the next three or so years.

Breville Group Ltd (ASX: BRG)

Breville is a leading example of an Australian business that has successfully expanded overseas. It’s best-known for its Breville brand of coffee machines and other small appliances, but it also owns Sage, Lelit, Baratza and Beanz.

It looks like a good time to consider the Breville share price because it has fallen more than 20% since August 2025, as the below chart shows.

While the operating environment is more challenging than it was a couple of years ago, the business continues to grow globally.

In the FY26 half-year result, its dominant global product segment saw Americas revenue growth of 11.6% to $549.5 million, Asia Pacific revenue growth of 5.9% to $190.3 million and EMEA (Europe, the Middle East and Africa) growth of 13.7% to $233.8 million.

I believe the business is well positioned to continue delivering double-digit revenue improvement as it expands in markets where there’s plenty of room for growth for coffee consumption such as South Korea and China.

Once the business has finished adjusting its manufacturing for the US market to countries without the same tariff negatives as China, then I think there’s good scope for strong profit growth for Breville.

According to the profit projection on CMC Invest, the Australian stock is forecast to grow profit by around 30% between FY26 to FY28. It’s currently valued at less than 24x FY28’s estimated earnings.

JB Hi-Fi Ltd (ASX: JBH)

JB Hi-Fi is a leading electronics and appliance retailer, with four different businesses – JB Hi-Fi Australia, JB Hi-Fi New Zealand, The Good Guys and E&S.

I believe this looks like a good time to invest because the JB Hi-Fi share price has fallen by 32% in the past year, as the below chart shows.

Higher inflation and interest rates may well be a headwind for the Australian stock in the shorter-term. But, sales performance remains solid – in the third quarter of FY26, JB Hi-Fi Australia sales were up 4% year over year, The Good Guys sales were up 2.5% and JB Hi-Fi New Zealand sales were up 23.2%.

I think JB Hi-Fi’s revenue and earnings are more defensive than the market is giving the business credit for, with consistent demand for things like phones, computers and appliances.

The business is predicted to generate $4.50 of earnings per share (EPS) in FY26, according to the forecast on CMC Invest. That puts the business at 16x FY26’s estimated earnings. It could also pay a FY26 grossed-up dividend yield of 6.8%, including franking credits.

The post 2 strong Australian stocks to buy now with $9,000 appeared first on The Motley Fool Australia.

More reading

• 3 popular ASX 200 shares that experts rate as strong buys
• 2 of the best ASX 200 shares to buy with $10,000
• 2 high-quality ASX 200 shares experts rate as buys
• I’d buy these 3 ASX shares before the next market rally
• 5 ASX retail shares whose 12-month price targets just got slashed

Motley Fool contributor Tristan Harrison has positions in Breville Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Codan Ltd (ASX: CDA) is not usually the first name investors think of when looking for defence exposure.

DroneShield Ltd (ASX: DRO) and Electro Optic Systems Holdings Ltd (ASX: EOS) are the usual candidates.

And while they are great options, I think Codan is an ASX 200 defence stock that deserves more attention.

The company has a mix of businesses that gives it exposure to several interesting long-term themes, including communications, defence, public safety, and gold detection.

That combination gives Codan more than one way to grow.

Mission-critical technology

The part of Codan I find most interesting is its communications business.

This division provides radio and tactical communications technology used in defence, security, emergency services, and other mission-critical environments.

These customers need equipment that works in difficult conditions, when reliability can be extremely important.

That is a very different market from consumer electronics.

I like businesses that serve demanding customers with specialised products. If the technology performs well, the customer relationship can be sticky and the brand can build credibility over time.

Defence and public safety spending can also have long-term support as governments focus more on security, resilience, and modernising equipment.

Codan is not a giant defence prime, and it will not suit investors looking only for large-scale weapons exposure. But I think its niche could be valuable.

Gold gives it another lever

Codan also owns Minelab, its metal detection business.

This gives the company exposure to recreational, artisanal, and professional gold detection demand. When gold prices are strong, interest in gold detecting equipment can improve.

I do not think Codan should be valued only as a gold-price play. That would be too narrow.

But I do like that Minelab gives the company another source of earnings that is different from tactical communications. It adds variety to the business and can perform well when demand for gold detection is strong.

The challenge is that detector demand can be cyclical. Product cycles are important, competition can affect sales, and some markets can be uneven.

But Codan has a long history in this category, and I think Minelab remains a valuable asset inside the group.

Why I’d buy

What I like about Codan is that it does not need one theme to do all the work.

The communications business can benefit from defence, public safety, and mission-critical technology demand. Minelab can benefit from gold strength and new product cycles.

That mix makes Codan different from many ASX industrial and technology shares.

There are risks to be mindful of. Government and defence-related sales can be lumpy, product execution matters, and currency movements can affect results. Investors should also expect some uneven periods, because this is not a simple recurring revenue software business.

But I think Codan has enough quality, specialist capability, and global opportunity to remain interesting.

Foolish takeaway

Codan may not have the same profile as some of the more obvious defence or technology shares on the ASX.

The company sits in specialised markets where reliability, product quality, and customer trust matter. It also has a gold-linked business that can add upside when conditions are favourable.

For investors looking for something a little different, I think Codan could be one of the more overlooked ASX shares to watch.

The post Forget DroneShield and EOS, could this ASX 200 defence stock be one of the best to buy? appeared first on The Motley Fool Australia.

More reading

• DroneShield shares in focus amid FIFA World Cup update
• Why EOS, Life360, Nufarm, and Web Travel shares are pushing higher today
• Codan just acquired a US defence specialist. What does this mean for investors?
• Up 400%+: Does Bell Potter think EOS shares can keep rising?
• The SpaceX IPO is coming. Here are 2 ways investors could benefit from the space boom

Motley Fool contributor Grace Alvino has positions in Codan and DroneShield. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield and Electro Optic Systems. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Chorus Ltd (ASX: CNU) share price is in focus after the company published its 2025 fibre regulatory report, revealing a lift in its regulated asset base to $6.0 billion and a $76.3 million wash-up balance to be carried forward.

What did Chorus report?

• Regulated Asset Base increased from $5.9 billion in 2024 to $6.0 billion for 2025
• Core RAB reached $5.1 billion, up $0.2 billion from 2024
• Financial Loss Asset reduced to $0.9 billion in 2025
• 2025 revenues were $101 million below the maximum allowed
• Operating costs for 2025 totalled $94 million (H2) and $97 million (H1) for core fibre
• $129 million in capital expenditure in H2 2025, $178 million in H1 2025

What else do investors need to know?

The 2025 information disclosure highlights Chorus’ ongoing investments in expanding and maintaining its fibre network, with $343 million in new RAB assets commissioned during the year. The wash-up balance of $76.3 million, stemming from under-earning allowed revenue, will be carried forward to the next regulatory price-quality period (PQP3).

Chorus noted that both its financial numbers and regulatory calculations remain subject to review by the Commerce Commission. The company has also provided more detail for investors on its disclosures webpage.

What’s next for Chorus?

Looking ahead, Chorus is focused on supporting fibre connectivity across New Zealand and optimising its regulatory position for PQP3. The company continues to invest in upgrading its network assets and managing costs as it meets both customer needs and regulatory obligations.

Further updates are expected as the Commerce Commission reviews the submitted disclosures and as Chorus refines its strategy for future periods.

Chorus share price snapshot

Over the past 12 months, Chorus shares have declined 8%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 2% over the same period.

View Original Announcement

The post Chorus’s 2025 regulatory report: RAB grows, revenue falls short appeared first on The Motley Fool Australia.

More reading

• Judo upsizes $750m securitisation to boost capital and ROE
• 5 things to watch on the ASX 200 on Friday
• Here are the top 10 ASX 200 shares today
• 5 things to watch on the ASX 200 on Thursday
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The ASX share market is an incredible vehicle for growing wealth. But, it’s also one of the most volatile types of assets we could invest in.

But, I don’t view volatility as a problematic risk, it’s just something to watch with curiosity. We don’t have to act when the market is going through extraordinary gyrations.

I think there are a few factors that investors should keep in mind with ASX shares, or any type of shares, particularly in this period of uncertainty with higher inflation, interest rate uncertainty, conflict, energy costs and so on.

Unknown events regularly happen

The Iran war took the global investment community by surprise, leading to a sizeable market drop.

The US tariffs last year were a big surprise, leading to a big drop.

Inflation in 2022 and 2023 was surprising for the market, significantly hitting share prices.

COVID-19 led to a major decline of the ASX share market, with a huge fall of valuations during 2020.

Each of those events were a one-off. But, something happens so regularly that I’ve just become accustomed to the volatility and I view those times as buying opportunities because of my confidence that normality will resume sooner or later.  

It’s not just my positive mindset that gives me confidence to invest and hold during uncertain periods. History has shown how the world typically bounces back. Additionally, many leaders and institutions are trying to help the country navigate negative periods, as we saw during COVID-19 (and the GFC).

There are always opportunities

Sometimes the market is priced very negatively and other times very highly – occasionally hitting a new all-time high – and it can feel hard to invest at those times.

During market highs, not everything is trading at an all-time high, there are usually pleasing opportunities hidden underneath the surface, even if the blue-chips are trading attractively.

Smaller names and certain sectors can be mis-priced by the market if investors aren’t taking into account where an investment could be in three years from now.

For example, right now, I think several real estate investment trusts (REITs) like Rural Funds Group (ASX: RFF) and Centuria Industrial REIT (ASX: CIP) are attractively priced because of fears about higher interest rates.

Also, certain ASX tech shares look significantly oversold because of AI worries, such as Siteminder Ltd (ASX: SDR), Pro Medicus Ltd (ASX: PME) and TechnologyOne Ltd (ASX: TNE).

When markets fall, I get particularly excited when the market suffers a widespread sell-off because there are opportunities galore.

Long-term investing filters out the noise

One of the main reasons why I’m not at all bothered by significant volatility is because I’m investing for many years to come.

If we’re investing with 2030 or 2040 in mind, does it really matter what happens in 2026 or 2027? I don’t think it should.

I try to only invest in ASX shares that I’m holding for the long-term and that I’d be excited to buy more of if the share price fell. That way, market declines seem like significant opportunities rather than something to worry about.

If the market rises or falls from here, I won’t let it affect my strategy – invest in good investments with compelling futures, at valuations that aren’t too expensive.

The post How to invest in ASX shares during such an uncertain period appeared first on The Motley Fool Australia.

More reading

• 2 ASX 200 shares that could dominate the next decade
• 2 excellent high-yield ASX dividend stocks I’d buy today
• 3 top ASX dividend shares to boost your passive income in June
• Here are the top 10 ASX 200 shares today
• Why Galan Lithium, Life360, Select Harvests, and Siteminder shares are storming higher

Motley Fool contributor Tristan Harrison has positions in Pro Medicus, Rural Funds Group, SiteMinder, and Technology One. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended SiteMinder and Technology One. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Rural Funds Group and SiteMinder. The Motley Fool Australia has recommended Pro Medicus and Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Australia’s superannuation system is one of the most powerful wealth creation engines on the planet.

The pool now exceeds $4.5 trillion in total assets.

It grows every fortnight as 12% of every Australian worker’s salary flows in by law.

And as the population ages, an increasing proportion of that capital is moving from industry and retail mega-funds toward independent advisers who use wealth management platforms to administer their clients’ money.

Three ASX-listed companies sit directly in the path of that shift.

Hub24 Ltd (ASX: HUB)

Hub24 has been one of the standout performers on the ASX over the past five years, rising significantly as advisers migrated from legacy platforms to its modern, technology-first alternative.

The numbers confirm the momentum is not slowing.

In Q3 FY 2026, Hub24 delivered $4.0 billion in net platform inflows, bringing total funds under administration to $151.7 billion, up 22% year on year.

More than 5,200 advisers now use the Hub24 platform, up 11% year on year, and the company has ranked first for quarterly net inflows for nine consecutive quarters.

Hub24 upgraded its FY 2027 platform FUA target to $160 billion to $170 billion, and is rolling out its myhub AI ecosystem.

This will integrate advice tools and technology into a single platform, providing an even stronger product that will drive future growth.

Netwealth Group Ltd (ASX: NWL)

Netwealth is Hub24’s closest rival and is equally well-positioned to capture the superannuation growth story.

Netwealth’s first-half FY 2026 result sent shares surging 10% in a single session, with platform FUA reaching a record as revenue and earnings grew at double-digit rates.

The company has built a reputation for product quality and client retention that rivals Hub24’s.

Both companies are raising capital faster than Australia’s largest industry super funds, a remarkable achievement for businesses that were virtually unknown a decade ago.

Netwealth has also slipped in recent weeks alongside Hub24, creating a more attractive entry point for investors.

Perpetual Ltd (ASX: PPT)

Perpetual offers a different angle on the superannuation theme.

Rather than a platform business, Perpetual is one of Australia’s oldest investment management firms, overseeing $219.2 billion in assets under management across global equity and fixed income strategies.

The company is in the middle of a significant transformation, having announced the $500 million sale of its Wealth Management division to Bain Capital.

This will reduce net debt to approximately 0.2 times EBITDA and sharpen its focus on institutional asset management.

A cleaner balance sheet and renewed strategic focus have attracted growing broker interest.

For investors seeking exposure to the superannuation theme through a more value-oriented lens, Perpetual’s post-sale transformation looks increasingly interesting.

Foolish Takeaway

Australia’s compulsory superannuation system means the pool keeps growing regardless of what markets do.

Hub24 and Netwealth capture that growth through platform market share gains.

Perpetual captures it through institutional asset management.

All three are positioned to benefit from a multi-decade tailwind that most investors are underestimating.

The post Why Australia’s $4 trillion superannuation pool is creating a once-in-a-generation opportunity for these ASX stocks appeared first on The Motley Fool Australia.

More reading

• Why I think this could be one of the best ASX 200 growth shares to buy
• 2 of the best ASX 200 shares to buy and hold for 10 years
• 3 ASX shares that could build serious wealth for shareholders
• Down 40%+! I’d buy CSL and these ASX shares while investors are still cautious
• Where I’d invest $5,000 in ASX shares this week

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24 and Netwealth Group. The Motley Fool Australia has positions in and has recommended Netwealth Group. The Motley Fool Australia has recommended Hub24. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Judo Capital Holdings Ltd (ASX: JDO) share price is in focus after the bank announced a successful $750 million securitisation of SME loans, increasing its Common Equity Tier 1 (CET1) ratio and boosting return on equity (ROE).

What did Judo Capital report?

• Completed a $750 million capital-relief securitisation, upsized from the original $500 million.
• The notes priced at a weighted average of 171 basis points over 1-month BBSW, 102bps tighter than the previous deal.
• Pro forma CET1 ratio at 31 March 2026 is 13.2%, up from 12.6% reported.
• The transaction is expected to be accretive, providing a 25–30bps pro-forma benefit to FY27 ROE.
• No impact on gross loan reporting or interest income.

What else do investors need to know?

The success of the transaction, backed by Judo’s portfolio of SME business loans, reflects strong demand from both domestic and international investors. By qualifying for regulatory capital relief, Judo can lend more flexibly while simultaneously improving profitability.

Importantly, the underlying loans remain on Judo’s books, so the bank continues earning interest on them. As a result, Judo will see an immediate uplift in ROE without the need to allocate as much capital to these loans.

Settlement for this securitisation is expected on 4 June 2026. The transaction’s success also means Judo has more options to actively manage its capital in the future.

What’s next for Judo Capital?

After this transaction closes, Judo expects to keep supporting lending growth for Australian SMEs while further improving its financial strength and flexibility. Management has flagged the potential to explore additional capital management initiatives going forward.

With improved CET1 and uplifted ROE, Judo appears well positioned to continue its growth plans and reinforce its competitive position in the business banking sector.

Judo Capital share price snapshot

Over the past 12 months, Judo Capital shares have declined 6%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 2% over the same period.

View Original Announcement

The post Judo upsizes $750m securitisation to boost capital and ROE appeared first on The Motley Fool Australia.

More reading

• Chorus’s 2025 regulatory report: RAB grows, revenue falls short
• 5 things to watch on the ASX 200 on Friday
• Here are the top 10 ASX 200 shares today
• 5 things to watch on the ASX 200 on Thursday
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Imugene Ltd (ASX: IMU) shares were on form on Thursday.

The small-cap ASX healthcare stock charged higher following the release of an update on a key trial.

Let’s now see what Bell Potter is saying about the drug developer following the announcement.

What is the broker saying?

Bell Potter highlights that the first patient has been enrolled for cohort 3 for its Phase 1b trial.

That trial is investigating the concurrent dosing of azer-cel in combination with a BTKi for the treatment of rare forms of Non-Hodgkin’s Lymphoma (NHL).

The broker notes that patients must be refractory to at least one previous line of therapy, being either of the BTK inhibitors (BTKi) including Eli Lilly’s Pirtobrutinib.

Bell Potter has high hopes for the trial, speaking very positively about the rationale behind cohort three. It said:

The rationale for cohort 3 is relatively straight forward. BTKi and CAR-T are the SOC across multiple haematological cancers. The recent proof of concept TARMAC study (n=20, being a concurrent combo of a BTKi with auto CAR-T) demonstrated an 80% complete response rate in R/R MCL patients, however, toxicity was not insignificant with 20% CRS ≥ G3. The investigators concluded that the addition of a BTKi greatly enhanced the performance of CD19 directed CAR-T result in long DoRs.

The potential advantage of azer-cel is its off the shelf availability and favourable safety profile. Patients in TARMAC were required to [be] eligible for auto CAR-T, i.e. able to survive the 4 week manufacturing period. Access to auto CAR-T is severely limited for this patient group who typically have no remaining treatment options and very poor survival outlook. Patients with uncontrolled disease also have heightened risk of more severe adverse events.

Bell Potter believes it won’t take long for full enrolment of the trial, with data potentially starting to be known within weeks. The broker adds:

The off-shelf availability of both azer-cel and BTKi therapies will expand eligibility, hence we expect rapid enrolment of ~20 patients in this cohort. Patients will be monitored for ongoing duration of response (DoR), however, short term tumour responses will be known within weeks. Separately, ASCO takes place this weekend. IMU has an oral presentation of data from an earlier cohort involving treatment of 19 patients with various forms of NHL naïve to CAR-T therapies but excluding MCL. This group achieved an ORR of 81% with DoR still maturing.

Should you invest?

If you have a high tolerance for risk, then Bell Potter thinks this could be an ASX healthcare stock to buy.

This morning, the broker has reaffirmed its speculative buy rating and 25 cents price target on Imugene’s shares. This is more than double its current share price.

The broker concludes:

Treatment of R/R NHL remains a clear unmet need both from safety and efficacy standpoint. We eagerly await data from this latest cohort in 2H CY26.

The post Which ASX healthcare stock could rise over 100% according to Bell Potter? appeared first on The Motley Fool Australia.

More reading

• Guess which ASX biotech stock could rise over 150%

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

On the ASX share market, we can find businesses with high dividend yields, perhaps as high as 10% or more.

The average return of the ASX share market over the long-term has been around 10%. How great would it be to receive that level of return just from the cash payments?

Of course, higher yields do come with their risks. That yield may be high because investors are expecting the business’ profit and payout to reduce sooner rather than later. Or, the yield could be really high because the dividend payout ratio is unsustainably high.

The following two businesses currently offer yields above 10%.

I don’t know what size the payouts will be in the coming years, but I expect the dividend yields will remain very high for the foreseeable future, keeping in mind the payout could be reduced somewhat from where it is today.

Let’s find out about those two businesses.

Centuria Office REIT (ASX: COF)

This business is a real estate investment trust (REIT) that owns office properties across Australian metropolitan locations.

The share price has suffered a significant decline over the last few years because of the headwinds of work-from-home and higher interest rates.

However, it’s still generating plenty of rental income and is signing new leases. In the FY26 third-quarter update, it reported that during the period, 5,742sqm of lease terms were agreed across 11 transactions including 2,263sqm of new leases and 3,479sqm of renewals with the majority of these transactions in Brisbane.

Pleasingly, the business reported a re-leasing spread of 8.6%, with strong rental growth from the Fortitude Valley and Hamilton assets.

The ASX share’s portfolio currently has a four-year weighted average lease expiry (WALE), with a 90% portfolio occupancy, which I’d view as solid statistics, considering all of the factors going on.  

Additionally, it also reported it has refinanced $1 billion of debt refinancing across its debt book, resulting in a 30 basis point (0.3%) debt margin reduction and an extension of the weighted average debt expiry from 2.6 years to 4.3 years.

The business highlights limited supply of new office space, with there being a “significant disconnect between replacement costs and current valuations”.

The ASX share also noted that the “widening gap of economic rents to prevailing market rents not only prohibits feasible office development but provides ample room for current market rents to continue to grow and underpin future valuations.”

Its expected FY26 distribution of 10.1 cents per security translates into a dividend yield yield of around 11%.

WAM Microcap Ltd (ASX: WMI)

WAM Microcap is a listed investment company (LIC) that invests in small ASX shares with big growth potential.

Any sized business can produce returns, but the smaller we go down the market capitalisation list, the less-researched the stocks are and the better potential they have to produce stronger strong returns.

Past performance is not a guarantee of future returns of course, but WAM Microcap’s portfolio has returned an average of 14.2% since its inception in June 2017, before fees, expenses and taxes. Those returns have been large enough to pay a very sizeable dividend.

It expects to slightly increase its annual dividend per share to 10.7 cents per share. That translates into a grossed-up dividend yield of 10.75% from the ASX share.

Of the two names I’ve highlighted, I’d rather buy WAM Microcap because it’s increasing its payout and it offers diversification. But, the REIT could be significantly undervalued at this level.

The post 2 ASX shares with dividend yields above 10% appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Southern Cross Gold, Healius, Centuria Office REIT shares
• How much is needed in superannuation to target a $3,000 monthly passive income?
• How much is needed in superannuation to target a $7,500 monthly passive income?
• Get paid huge amounts of cash to own these ASX dividend shares
• Why I think this ASX dividend share with a 9.5% dividend yield is a buy

Motley Fool contributor Tristan Harrison has positions in Wam Microcap. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Select Harvests Ltd (ASX: SHV) shares were on form on Thursday.

The ASX 300 stock ended the session around 8% higher at $3.90.

But if you thought the gains were over, think again.

That’s because Bell Potter believes the almond producer’s shares could be destined to deliver even greater returns over the next 12 months.

What is the broker saying about this ASX 300 stock?

Bell Potter notes that Select Harvests delivered a result that was short of expectations in the first half of FY 2026.

However, it points out that this was due largely to the timing of third-party processing and VAP revenues. It explains:

SHV reported 1H26 underlying NPAT below our forecasts at $29.1m (vs. BPe $41.2m) largely driven by timing of third party processing and VAP revenues. Key result metrics include: Operating results: Revenue of $59.0m was down -44 % YoY (vs. BPe $104.4m). Operating EBITDA of $62.6m was up +8% YoY (and vs. BPe of $77.6m). Operating NPAT was up +8% YoY to $29.1m (and vs. BPe of $41.2m). 1H26 results are predicated on a crop of 29,500t (vs. BPe of 29,000t and 1H25 of 25,250t) and an almond price of A$10.21/kg (vs. BPe of A$10.00/kg).

Elevated drying costs have been largely mitigated by volume and pricing outcomes, with the weaker result reflecting the timing of revenue recognition from third party processing (in 2H26e and up ~8,000t YoY) and VAP sales (with 20% processed vs. 35% in 1H25).

The ASX 300 stock’s outlook was better. Bell Potter highlights:

Key outlook comments include (1) A FY26e crop forecast of 28,000-31,000t and orchards costs of $219.6m, which would imply Farming EBIT of $66-98m at the 1H26 price of $10.21/kg (BPe of $81m); (2) 2H26e to see the financial benefit of external grower volumes (~8,00/t YoY) and VAP sales (on SHV’s crop); (3) SHV announced an up to 10% share buyback and a 3.5¢ps DPS (the first dividend since 2022); and (4) announced Optimus phase 4 looking to lift processing capacity to 65,000t (from 55,000t) and targeting $700m revenue by FY30e.

Big potential returns

In response to the results, Bell Potter has retained its buy rating and $5.30 price target on the company’s shares.

Based on its current share price of $3.90, this implies potential upside of 36% for investors over the next 12 months.

In addition, a 2.6% dividend yield is expected over the same period.

Bell Potter concludes:

SHV continues to deliver on cost and growth initiatives to improve earnings quality and is executing in an environment where the California bearing acreage is in contraction, implying a more favourable pricing backdrop over FY26-28e.

The post Bell Potter says this ASX 300 stock can storm 36% higher appeared first on The Motley Fool Australia.

More reading

• Why Galan Lithium, Life360, Select Harvests, and Siteminder shares are storming higher
• This company has just announced a buyback, and the shares are surging
• ASX 200 consumer staples shares outperformed again last week
• Buy, hold, sell: Superloop, Hansen Technologies, Select Harvests shares

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares fell 1.43% to 8,592.9 points yesterday amid no progress on US-Iran negotiations.

Let’s check out some new ratings on three ASX shares.

Southern Cross Gold Consolidated Ltd (ASX: SX2)

This ASX gold share closed at $9.50, down 4.4% yesterday.

The Southern Cross Gold share price has risen by more than 60% over 12 months.

Shaw and Partners has a buy rating on the gold explorer. 

The broker gives Southern Cross Gold shares a 12-month price target of $14.40 based on a discounted cash flow (DCF) valuation.

Analyst Alex Barkley said:

Our base case forecasts support our Buy Recommendation, with an implied ~40% stock upside.

We also find substantial project upside potential at Sunday Creek.

Geological extension potential could extend mine life or importantly, allow a larger mining capacity.

Any project expansion returns could be supercharged by the remarkable ~9g/t AuEq site grade.

Key upcoming catalysts include ongoing drilling, an Exploration Target update in Q2 CY26, and a maiden Resource in Q1 CY27. 

Centuria Office REIT (ASX: COF)

Centuria Office REIT shares closed steady at 91 cents yesterday.

The ASX real estate investment trust (REIT) has fallen 27% over 12 months.

Bell Potter recently maintained its hold call on this ASX property share and lowered its target from $1.05 to 95 cents.

Analyst Michael Armstrong said:

COF is facing headwinds to earnings from tricky conditions in key exposed markets, rising interest rates, and dilutionary asset divestments.

We forecast earnings declining in FY27 (-2.7% below consensus), holding in FY28, before returning to growth in FY29.

COF screens inexpensive on a P/E and NTA basis but is trading at a P/E to Growth (PEG) ratio of 13.0x, placing it well above peers (sector simple avg. 2.9x).

We see better risk-adjusted opportunities in other sub-sectors at present and believe a pickup in the suburban market is still a little way off.

Healius Ltd (ASX: HLS)

This ASX healthcare share closed steady at 35 cents on Thursday.

The Healius share price has tanked 62% over 12 months.

After the company issued an FY26 earnings downgrade, Jarden kept its sell rating in place.

The broker has a price target of 47 cents, which implies 34% capital growth ahead.

The post Buy, hold, sell: Southern Cross Gold, Healius, Centuria Office REIT shares appeared first on The Motley Fool Australia.

More reading

• 2 ASX shares with dividend yields above 10%
• 5 ASX shares downgraded by brokers this week
• Buy, hold, sell: Aristocrat, Breville, and Healius shares
• Why is this ASX 300 share crashing over 20% today?
• Why CBA, Healius, Paladin Energy, and Temple & Webster shares are sinking today

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.